ThermoGenesis Holdings, Inc. · OTC:THMO

ThermoGenesis — Merger or Acquisition (July 2013)

30 slides from ThermoGenesis's merger presentation, Jul 18, 2013

  1. Slide 1: Corporate Presentation: The Merger of ThermoGenesis & TotipotentRX

    Exhibit 99.1 Filed by: ThermoGenesis Corp. Pursuant to Rule 425 under the Securities Act of 1933 ‘Subject Company: ThermoGenesis Corp. ‘Commission File No.: 333-8290 fCESCA Therapeutics Corporate Presentation The Merger of ThermoGenesis & TotipotentRX July 2013 Clinical Excellence in Stem Cell Appli

  2. Slide 2: Forward Looking Statement

    Cesca™ Therapeutics Forward Looking Statement This letter contains forward-looking statements. Such forward-looking statements include but are not limited to that the proposed merger will be consummated and that the resulting company will be able to become a fully integrated regenerate medicine comp

  3. Slide 3: First company to integrate devices, cell formulations and clinical steps

    Cesca Therapeutics is (to our knowledge) the first company to integrate all of the essential: 1. Cell friendly devices, 2. Proprietary cell formulations, and • Strict clinical steps to ensure the autologous therapy is precisely delivered and predictable . 3. Using our own CRO, not only saves signifi

  4. Slide 4: TotipotentRx operational in the clinical space since 2007

    TotipotentRx has been operational in the clinical space since 2007, and the Founders and senior team have more than 50 years of combined experience in the cell therapy space. TotipotentRx's leadership Board prior to the merger encompasses scientists, physicians, and former healthcare investment bank

  5. Slide 5: ThermoGenesis snapshot

    Cesca Therapeutics ThermoGenesis snapshot (Nasdaq: KOOL) + Leading designer and supplier of clinical technologies for processing, storage and administration of stem cells, + Core capabilities include quality innovation, design IP, commercialization, regulatory, and global distribution ~$18M in annua

  6. Slide 6: Regenerative medicine is the future of healthcare

    Regenerative medicine is the future of healthcare, and we must find more innovative and cost effective ways of treating our aging population. As we live longer, the dependency on chronic health supportive therapies grows and the long term economic impact of this is not sustainable. Obviously, the id

  7. Slide 7: Promise of stem cells and shift toward autologous cells

    There has been significant news about the promise of all types of stem cells, including embryonic, reprogrammed cells, and expanded cells (cells in a bottle) – otherwise known as allogeneic cells. However, most of these are interesting scientifically, but are reasonably far from commercialization du

  8. Slide 8: Commercial position of autologous cell therapy

    Having just talked about the academic growth in cellular medicine, we also need to understand the commercial position. Allogeneic cell development presents some level of safety risk, which may not be offset by the potential benefit. However, autologous therapies are not without limitations, among th

  9. Slide 9: Cesca's focus on autologous therapies

    Cesca has addressed these concerns, and is focused on delivery of autologous therapies which are: • Collected from and delivered to the patient in a single procedure (Patient Friendly) • Protocol driven giving the physician complete instructions for treatment (Physician Friendly) • Completed at the

  10. Slide 10: Comparison of integrated approach with competitors

    Having talked about the need to optimize the therapy by integrating all components (i.e. fully integrated) as recommended to industry by the U.S. FDA, we have compared our approach and experience to our competitors. Remember, ThermoGenesis has been producing clinical devices for over 20 years, and T

  11. Slide 11: CellWerks process versus typical clinical development

    Comparing our unique process, proudly called CellWerks™, to typical clinical development will better elucidate why we believe we have such a strong competitive advantage. As we have mentioned, there are significant variable influencing points (physical, environmental, chemical etc.) where clinical r

  12. Slide 12: SurgWerks combination product kits

    Having developed, in our opinion, the ideal process for developing a bedside based autologous therapy, we have taken the next step of creating treatment specific therapies as integrated "combination product" kits which we call SurgWerks ™. Each SurgWerk indication specific kit will contain all of th

  13. Slide 13: Pioneering combination products and IP protection

    We believe we are pioneering in this field by delivering the first combination products as defined by the U.S. FDA in 21 CFR 3.2(e), and further anticipate that the Center for Biologics Evaluation and Research ("CBER") will have ultimate oversight of our products as the cells are the most active ele

  14. Slide 14: Lower risk in gaining regulatory approval

    Going beyond our sustainable clinical and I.P. advantages, we also believe another advantage is our lower risk in gaining regulatory approval. This is based on a regulatory risk decision tree matrix which appears reasonably consistent across most jurisdictions. Our products thus far are: 1. Autologo

  15. Slide 15: Dialing in a therapeutic dose

    Even though our cells are autologous, and therefore generally a lower safety risk, we still have the capability to "dial in" an therapeutic dose. Using our "smart vision system" and corresponding indication specific firmware algorithm, we can create a therapeutic ideally optimized for the transplant

  16. Slide 16: Completed clinical trials and six indications

    TotipotentRx has completed ten (10) clinical trials to date and ThermoGenesis has completed two (2) pilot trials to date. We are highlighting seven (7) of them here. Our plans call for pursuing commercialization of six (6) clinical indications which combined have an addressable market of almost $17B

  17. Slide 17: Critical Limb Ischemia Phase 1b trial

    The Critical Limb Ischemia ("CLI") Phase 1b trial enrolled 17 patients who were considered "no option" patients. CLI is the last phase of peripheral vascular disease, where the leg is so deprived of blood flow and oxygen, that it has visible signs of gangrenous ulceration. In each of these cases the

  18. Slide 18: Non-union fracture study

    Another study we completed was on 19 non-union fracture patients. A long bone fracture is considered to be non-uniting (non healing) if it has failed to fuse 6 months after surgical fixation. In this study we collected the patients bone marrow stem cells, processed them on a ThermoGenesis device, co

  19. Slide 19: Six indications advancing to next clinical stage

    The company has selected six (6) indications to advance to the next level of clinical trial evaluation. We currently have approval for a Phase 1b in acute myocardial infarction and non-healing ulcers, and will be seeking permission to conduct Phase 1b trials in ischemic stroke, spinal fusion, osteoa

  20. Slide 20: Fortis Healthcare partnership

    Fortis Healthcare is one of the premier healthcare organizations globally, and operate in 6 countries worldwide (India, UAE, Hong Kong, Singapore, Mauritius, and Canada). This partnership not only provides excellent clinical staff and world class secondary and tertiary care hospitals, but provides a

  21. Slide 21: Partners and prospects for out-licensing

    Fortis is one of our most important partners, but we also envisage many others as we grow both our therapeutics and cord blood businesses. As mentioned, we have developed certain therapies which we may elect to out-license or enter co-development agreements. This is a partial list of high potential

  22. Slide 22: Accelerating growth in cord blood

    The combination of our companies will also accelerate our growth in the cord blood space, further jointly unlocking intrinsic value. We will leverage the: • ThermoGenesis' first mover position in Asia with TotipotentRx's regional service center • Grow our European business with TotipotentRx's strong

  23. Slide 23: Cord blood organic growth plan

    The cord blood organic growth plan is already in full force, and will continue to grow by leveraging key relationships like Golden Meditech and China Cord Blood Corporation. The remarkable growth of cord blood banking and clinical use has expanded faster in Asia than any other region over the past 2

  24. Slide 24: Key milestones for stockholder value

    Delivering stockholder value will require execution of key milestones in both the therapeutics and cord blood businesses. Cesca has identified, mapped and scheduled a stockholder communication plan which will demonstrate how we are tracking the business plan. As you can, many of these are highly foc

  25. Slide 25: Expected valuation expansion versus peers

    We expect meaningful valuation expansion as we transform our company into a regenerative medicine company. The market capitalization in our therapeutic peer group generates revenue multiples in a range between 12x and 22x. Applying even the low end of the range, a 12X multiple to Cesca's anticipated

  26. Slide 26: Growth capital investment

    Cesca Growth Capital Investment 36 month horizon + Clinical Development & Regulatory Initiatives - AMI, Stroke, OA, NHU $15M = CLI, Spine, NUF, AVN + Product Commercialization ~ Cord Blood (Distribution, Launches) 2M - Clinical Commercial Zones + Device Development & General Capital Reqs $3M ~ Diagn

  27. Slide 27: Senior leadership team of Cesca

    The senior leadership team of Cesca is a seasoned group with proven track records to position the company for achieving leadership in the autologous therapeutic space.

  28. Slide 28: Conclusion: three points on integration

    In conclusion and restating our plans in three points, on integration Cesca will be: The first integrated regenerative medicine company – meaning within one organization Cesca possesses the device platforms, therapeutic development and clinical testing through an in-house CRO, and the pioneering app

  29. Slide 29: Additional Information: Non-Solicitation

    29 Page: Cesca Therapeutics Additional Information Non-Solicitation = This presentation and the information contained herein shall not constitute an offer to sell, buy or exchange or the solicitation of an offer to sell, buy or exchange any securities, nor shall there be any sale, purchase or exchan

  30. Slide 30: Thank you

    Thank you \

Thermogenesis — Merger or Acquisition (July 2013) on 6ix